Bacteroides dorei as Next Generation Probiotics

It is increasingly recognized that Bacteroides dorei (B. dorei) plays a pivotal role in the development of several kinds of diseases such as cardiovascular disease and metabolic disease. Creative Biolabs has rich experience in developing and producing live biotherapeutic products, with both aerobic and anaerobic organisms. We now provide customized B. dorei-based drug discovery services and products for global clients. Our commercial products are strains of B. dorei which have been originally isolated from healthy human donors. They are grown in our cGMP-certified facility, encapsulated, and delivered selectively to the gut where they exert their therapeutic effects. Each strain is selected for its functionality in a similar way to how a small-molecule or biologic is selected to perform a specific role in combating a disease.

B. dorei Introduction

B. dorei is a species of bacteria within the genus Bacteroides. It is a gram negative, rod-shaped bacterium that contributes to normal intestinal functionality for humans and animals. B. dorei was isolated and differentiated from Bacteroides vulgatus (B. vulgatus) by using 16S rRNA sequencing and phenotypic tests in 2006. Research is being conducted to better understand the relationship B. dorei has on the human intestinal system and the autoimmune disease, type 1 diabetes (T1D).

B. dorei and Disease

Cardiovascular Disease

B. dorei is known to participate in the development of atherosclerotic cardiovascular disease. Analysis of gut microbial profile in patients with coronary artery disease (CAD) shows a relative depletion of B. vulgatus and B. dorei compared with controls without CAD with coronary risk factors. Gavage with live B. dorei decreases fecal and plasma lipopolysaccharide levels and protects against atherosclerosis in apolipoprotein E-deficient mice. Studies suggest that B. dorei treatment may serve as a novel and attractive therapeutic strategy for suppressing lipopolysaccharide-induced inflammatory response in CAD.
The microbial community in the human colon contains bacteria that reduce cholesterol to coprostanol. Strain D8 was isolated from a 10^-8 dilution of a fresh stool sample provided by a senior male volunteer with a high capacity to convert cholesterol to coprostanol. B. dorei D8 has been shown to reduce luminal cholesterol to coprostanol in vitro and may be considered as a probiotic in the context of the cholesterol-cardiovascular-disease axis.

Fig.1 Chemical structures of cholesterol and coprostanol. (Gérard, 2007)

Metabolic Disease

Besides the well-known direct effects of microbiota on the immune system, there are also indirect ways to affect autoimmunity, first and foremost the molecular mimicry process. In this perspective, there is long-time evidence about gut alterations leading to the development of T1D. Finally, studies revealed that B. dorei seems to dominate the gut microbiome in children at high risk for T1D.

Cancer

The tumor-specific Thomsen-Friedenreich antigen (TFα) is an attractive target for TFα-positive cancer treatment. A strain of B. ovatus, when fed to mice, increased levels of anti-TFα immunoglobulin (Ig) M (IgM) and IgG antibodies. Thus, this specific strain is a promising candidate for the development of the adjuvant-free anti-TFα-specific cancer vaccine.

Bacteroides dorei

Highlights of Our Bacteroides dorei Drug Discovery Services

Master and working cell bank preparation, validation, and storage
Fermentation and subsequent downstream purification
Downstream processing optimization and development
Multiple feed strategies and media options
Lyophilization or spray drying

The development of B. dorei-based live biotherapeutics offers a new way to create safe, effective, and convenient treatments for patients, presenting an opportunity to treat diseases that existing therapies are unable to effectively address. If you are interested in our services and products, please feel free to contact us for more information.

Reference

Gérard, P.; et al. (2007). Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces. Applied and environmental microbiology. 73(18), 5742-5749.